FDA.reportPublic FDA data

tocilizumab-aazg 162 MG per 0.9 ML Auto-Injector

RxCUI
2686045
RxNorm name
tocilizumab-aazg 162 MG per 0.9 ML Auto-Injector
Display name
tocilizumab-aazg 162 MG per 0.9 ML Auto-Injector
Full name
tocilizumab-aazg 162 MG per 0.9 ML Auto-Injector
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:15

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761275Tyennetocilizumab-aazg351(k) BiosimilarRx2026-07-01
761449Tyennetocilizumab-aazg351(k) BiosimilarRx2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
TYENNETOCILIZUMAB-AAZGFresenius Kabi USA, LLC87ac5047-4f2b-4571-a8a8-32e08865f3792026-07-23Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2686045
TYENNETOCILIZUMAB-AAZGFresenius Kabi USA, LLCad76441d-da59-47df-8d9d-2243005180f02026-06-03Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2686045

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
ad76441d-da59-47df-8d9d-2243005180f0tocilizumab-aazg 162 MG in 0.9 ML Auto-Injector [PSN] · 0.9 ML tocilizumab-aazg 180 MG/ML Auto-Injector [SCD] · tocilizumab-aazg 162 MG per 0.9 ML Auto-Injector [SY]34These highlights do not include all the information needed to use TYENNE safely and effectively. See full prescribing information for TYENNE. TYENNE ® (tocilizumab-aazg) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2024 TYENNE ® (tocilizumab-aazg) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful d20251126
87ac5047-4f2b-4571-a8a8-32e08865f379tocilizumab-aazg 162 MG in 0.9 ML Auto-Injector [PSN] · 0.9 ML tocilizumab-aazg 180 MG/ML Auto-Injector [SCD] · tocilizumab-aazg 162 MG per 0.9 ML Auto-Injector [SY]31These highlights do not include all the information needed to use TYENNE safely and effectively. See full prescribing information for TYENNE. TYENNE ® (tocilizumab-aazg) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2024 TYENNE ® (tocilizumab-aazg) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful d20250826